Vimta Labs524394Quarterly results

Q2 FY27 results with unmodified limited review; US wholly owned subsidiary noted

Board meeting outcome (30.10.2026): unaudited results for Q2 and H1 FY27 approved; Board took note of Vimta Labs LLC as a wholly owned subsidiary in the USA; 14,000 options granted under VLESOP-2021 on 26.10.2026.

By ScoutQuest · Fri 30 Oct 2026, 1:06 PM IST · 3 min read

1,119.83 (INR millions)+10%

30 Sep 251,018.48 (INR millions)30 Sep 261,119.83 (INR millions)

Revenue from operations: 1,018.48 (INR millions) (30 Sep 25) and 1,119.83 (INR millions) (30 Sep 26).

Q2 Revenue from Operations: 1,119.83 (INR millions) vs 1,018.48 a year earlier
Q2 Profit for the Period: 206.14 vs 199.20
ESOP Options Granted: 14,000 options granted under VLESOP-2021 on 26.10.2026

Results approved at the board meeting

The Board of Directors approved the unaudited financial results for the quarter and half year ended September 30, 2026. The Audit Committee reviewed and recommended them.
The statutory auditor, Gattamaneni & Co., Chartered Accountants, issued a limited review report stating that nothing came to its attention that causes it to believe the statement has not disclosed the required information or contains any material misstatement. In plain terms, an unmodified review conclusion.

Headline numbers (as printed, INR millions)

Revenue from operations: 1,119.83 for the quarter ended 30 Sep 2026, against 1,090.74 in the quarter ended 30 Jun 2026 and 1,018.48 in the quarter ended 30 Sep 2025.
Total income: 1,148.87 for the quarter; total expenses 873.62; profit before tax 275.25.
Profit for the period: 206.14 for the quarter and 416.56 for the half year.
Half-year revenue from operations: 2,210.57; half-year total income 2,277.73.
Earnings per share (face value Rs.2 per share): basic 4.61 and diluted 4.57 for the quarter; basic 9.32 and diluted 9.23 for the half year.

What else the Board dealt with

The Board took note of the incorporation of Vimta Labs LLC as a wholly owned subsidiary of the Company, further to the earlier intimation dated 06 May 2026.
The Nomination and Remuneration Committee, at its meeting held on October 26, 2026, granted 14,000 options to eligible employees under the Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021).

Balance sheet and cash (INR millions)

Total assets: 5,932.67 as at 30 Sep 2026, against 5,622.28 as at 31 Mar 2026.
Total equity: 4,913.59.
Cash and cash equivalents: 373.30 as at 30 Sep 2026, against 229.69 as at 31 Mar 2026.
Net cash generated from operating activities: 459.37 for the period ended 30 Sep 2026, against 1,471.42 for the year ended 31 Mar 2026.
Borrowings: 76.34 non-current and 68.00 current as at 30 Sep 2026.

Points from the notes

The company states it has only one reportable segment, Contract Research and Testing Services.
A public private partnership agreement with the Food Safety and Standards Authority of India dated June 29, 2021, to set up, operate and transfer a National Food Testing Laboratory at JNPT, Mumbai, is treated as a service concession arrangement; the right to charge customers for the services is assessed as an intangible asset.
Employee benefits expense for the quarter ended Sep 30, 2026 includes ₹ 9.43 million of share-based payment expense.
An incremental past service cost of ₹ 16.16 million arising from the new labour code was presented under exceptional items in the year ended March 31, 2026.
The company states it does not have any subsidiary/associate/joint venture entity during the quarter under review and the comparable periods.

How to read this

A results update of this kind tells you how the core business performed in the quarter and half year, and whether the auditor's review threw up any exception — here it did not. The segment and accounting notes explain how revenue and costs are recognised, and the stock option grant is a people-cost item that flows through employee benefits expense over the vesting period.

Also from Vimta Labs